Clinical Trials

Arizona Institute of Urology has a commitment to provide the most up to date and effective care for our patients. Part of this commitment can be fulfilled by our patient centered services - clinical trials. Through clinical trials we offer our patients the ability to take part in the continued progress of medicine and science. New treatments, both surgical and medical will be made available to our patients by our clinical trials team.

Clinical trials help the medical community to better understand disease and develop new medications, treatments and devices. Without clinical trials it is difficult to advance the care of many complex medical problems. At Arizona Institute of Urology, our physicians provide our patients with the opportunity to participate in this type of research, which offers the following potential benefits:

  • Access to promising treatments often not available outside the clinical-trial setting.
  • The study drug or treatment may be provided at no charge to patients.
  • Treatment that may be more effective than the standard approach.
  • Close monitoring, care and support by a research team of doctors and other health care professionals who understand your disease or condition. The research team that conducts clinical trials usually includes top doctors and scientists from around the United States and the world, all of whom will be working together with you. Because of this close monitoring, any side effects you might have are noticed and addressed immediately.
  • The feeling that you are taking an active role in your own health care and gaining a greater understanding of your disease or condition.
  • Contributing to research that may save lives in the future. Even if you don’t directly benefit from the results of the clinical trial you take part in, the information gathered can help others and adds to scientific knowledge.

People who take part in clinical trials are vital to the process of improving medical care. We are proud to be able to provide this valuable service.

The following clinical trials are being offered through Arizona Institute of Urology, PLLC:


  • Clinical Trial NCT02663908
    Ferring 000108 (PRONOUNCE)
    A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE) Enrolling
    - The purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease.
  • Clinical Trial NCT04179864
    A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer Starts 2/17/2020
    - This is global, multi-center, open-label, randomized phase 1b, active-controlled safety and efficacy study of oral administration of tazemetostat in combination with enzalutamide or abiraterone/prednisone versus enzalutamide or abiraterone/prednisone alone in asymptomatic or mildly symptomatic subjects with progressive, metastatic castration-resistant prostate cancer (mCRPC) who have progressed on either abiraterone acetate, enzalutamide, or apalutamide or who are second generation anti-androgen treatment naive, and who have not received chemotherapy for mCRPC. This study is designed to determine the recommended phase 2 doses (RP2D) of tazemetostat in combination with either enzalutamide or abiraterone/prednisone, based on safety, tolerability, pharmacokinetic, pharmacodynamic, and efficacy profiles.
  • Clinical Trial NCT04122976
    Bayer 20590 (Darol)
    A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described (DAROL)
    - The purpose of this study is to find out in the real-world setting, if darolutamide is safe and effective for patients diagnosed with prostate cancer that has not spread to other parts of the body. When a patient is enrolled to the study, his/her physician would have already made the decision to treat patient with darolutamide per local standard practice.



  • Clinical Trial NCT04228445
    Provepharm PVP-19IC01
    3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency (UP) Starts mid-February
    - This is an open-label, randomized, multicenter study to evaluate the efficacy, safety, and pharmacokinetics of two doses (2.5 mL and 5.0 mL) of 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium solution for injection when used as an aid in the determination of ureteral patency. Study will enroll up to 116 subjects from approximately 10 study centers in the United States.

Check back here often for current projects and updates.


Upcoming additional trials for prostate cancer, bladder cancer and for men who have an overactive bladder...

For more information about these studies or to learn how you can participate Contact us at 520-784-7019 or email